Publikationen von Bianca Sperl

Lutz, S. Z.; Hennige, A. M.; Peter, A.; Kovarova, M.; Totsikas, C.; Machann, J.; Krober, S. M.; Sperl, B.; Schleicher, E.; Schick, F. et al.; Heni, M.; Ullrich, A.; Haring, H.-U.; Stefan, N.: The Gly385(388)Arg Polymorphism of the FGFR4 Receptor regulates Hepatic Lipogenesis under healthy Diet. Journal of Clinical Endocrinology and Metabolism 104 (6), S. 2041 - 2053 (2019)

Berg, A.; Sperl, B.; Berg, T.: ATP Inhibits the Transcription Factor STAT5b. ChemBioChem: A European Journal of Chemical Biology 20 (17), S. 2227 - 2231 (2019)

Schueder, F.; Stein, J.; Stehr, F.; Auer, A.; Sperl, B.; Strauss, M. T.; Schwille, P.; Jungmann, R.: An order of magnitude faster DNA-PAINT imaging by optimized sequence design and buffer conditions. Nature Methods 16 (11), S. 1101 - 1104 (2019)

Grabner, A.; Amaral, A. P.; Schramm, K.; Singh, S.; Sloan, A.; Yanucil, C.; Li, J.; Shehadeh, L. A.; Hare, J. M.; David, V. et al.; Martin, A.; Fomoni, A.; Di Marco, G. S.; Kentrup, D.; Reuter, S.; Mayer, A. B.; Pavenstadt, H.; Stypmann, J.; Kuhn, C.; Hille, S.; Frey, N.; Leifheit-Nestler, M.; Richter, B.; Haffner, D.; Abraham, R.; Bange, J.; Sperl, B.; Ullrich, A.; Brand, M.; Wolf, M.; Faul, C.: Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy. CELL METABOLISM 22 (6), S. 1020 - 1032 (2015)

Ulaganathan, V. K.; Sperl, B.; Rapp, U. R.; Ullrich, A.: Germline variant FGFR4 p.G388R exposes a membrane-proximal STAT3 binding site. NATURE 528 (7583), S. 570 - 574 (2015)

Xiao, Z.; Sperl, B.; Ullrich, A.; Knyazev, P.: Metformin and salinomycin as the best combination for the eradication of NSCLC monolayer cells and their alveospheres (cancer stem cells) irrespective of EGFR, KRAS, EML4/ALK and LKB1 status. ONCOTARGET 5 (24), S. 12877 - 12890 (2014)

Gräber, M.; Hell, M.; Groest, C.; Friberg, A.; Sperl, B.; Sattler, M.; Berg, T.: Oral Disinfectants Inhibit Protein-Protein Interactions Mediated by the Anti-Apoptotic Protein Bcl-x(L) and Induce Apoptosis in Human Oral Tumor Cells. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION 52 (16), S. 4487 - 4491 (2013)

Hollis, A.; Sperl, B.; Graber, M.; Berg, T.: The Natural Product Betulinic Acid Inhibits C/EBP Family Transcription Factors. ChemBioChem 13 (2), S. 302 - 307 (2012)

Graeber, M.; Janczyk, W.; Sperl, B.; Elumalai, N.; Kozany, C.; Hausch, F.; Holak, T. A.; Berg, T.: Selective Targeting of Disease-Relevant Protein Binding Domains by O-Phosphorylated Natural Product Derivatives. ACS Chemical Biology 6 (10), S. 1008 - 1014 (2011)

Riechers, A.; Grauer, A.; Ritter, S.; Sperl, B.; Berg, T.; König, B.: Binding of phosphorylated peptides and inhibition of their interaction with disease-relevant human proteins by synthetic metal-chelate receptors. Journal of Molecular Recognition 23 (3), S. 329 - 334 (2010)

Wetzel, S.; Wilk, W.; Chammaa, S.; Sperl, B.; Roth, A. G.; Yektaoglu, A.; Renner, S.; Berg, T.; Arenz, C.; Giannis, A. et al.; Oprea, T. I.; Rauh, D.; Kaiser, M.; Waldmann, H.: A Scaffold-Tree-Merging Strategy for Prospective Bioactivity Annotation of gamma-Pyrones. Angewandte Chemie-International Edition 49 (21), S. 3666 - 3670 (2010)

Sperl, B.; Seifert, M. H. J.; Berg, T.: Natural product inhibitors of protein-protein interactions mediated by Src-family SH2 domains. Bioorganic & Medicinal Chemistry Letters 19 (12), S. 3305 - 3309 (2009)

Müller, J.; Sperl, B.; Reindl, W.; Kiessling, A.; Berg, T.: Discovery of chromone-based inhibitors of the transcription factor STAT5. ChemBioChem 9 (5), S. 723 - 727 (2008)

Kiessling, A.; Schust, J.; Müller, J.; Sperl, B.; Reindl, W.; Hollis, A.; Berg, T.: Small-molecule inhibitors of cancer-relevant protein-protein interactions. Onkologie 31 (Suppl. Suppl. 1), S. 16 - 16 (2008)

Kiessling, A.; Wiesinger, R.; Sperl, B.; Berg, T.: Selective inhibition of c-Myc/Max dimerization by a pyrazolo[1,5-a]-pyrimidine. ChemMedChem 2 (5), S. 627 - 630 (2007)

Schust, J.; Sperl, B.; Hollis, A.; Mayer, T. U.; Berg, T.: Stattic: A small-molecule inhibitor of STAT3 activation and dimerization. Chemistry & Biology 13 (11), S. 1235 - 1242 (2006)

Kiessling, A.; Sperl, B.; Hollis, A.; Eick, D.; Berg, T.: Selective inhibition of c-Myc/Max dimerization and DNA binding by small molecules. Chemistry & Biology 13 (7), S. 745 - 751 (2006)

Sperl, B.; Abraham, R.; Bussemer, J.; Wallasch, C.; Schwaiger, M.; Ullrich, A.: Visualization of tumor formation in the WAP-TGFa/FGFR4Arg385 KI breast cancer mouse model. In EUROPEAN JOURNAL OF CANCER, 50 (Suppl. 5), 417, S. S99 - S100. ELSEVIER SCI LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND (2014)

Ulaganathan, V. K.; Sperl, B.; Mayr, T.; Hornberger, R.; Rapp, U. R.; Ullrich, A.: A gain of function by the cancer-associated FGFR4 c. 1162G>A (p. Gly388Arg) variant. In EUROPEAN JOURNAL OF CANCER, 50 (Suppl. 5), 446, S. S107 - S108. ELSEVIER SCI LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND (2014)

Xiao, Z.; Sperl, B.; Ullrich, A.; Knayzev, P.: Combinatorial treatment of lung cancer cell lines and their spheroids-cancer stem cells with standard therapeutic drug and salinomycin. In EUROPEAN JOURNAL OF CANCER, 50 (Suppl. 5), 789, S. S190 - S190. ELSEVIER SCI LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND (2014)